Compare Ascendis Pharma A/S (ASND) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs KLA Corp. — how do they compare? Ascendis Pharma A/S trades at $263.79 (market cap $17.74B), while KLA Corp. trades at $224.01 (market cap $302.43B). The key difference: KLA Corp. is far larger — about 17× Ascendis Pharma A/S's market cap, and KLA Corp. pays a 0.4% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | KLAC | |
|---|---|---|
Market Cap | $17.74B | $302.43B |
Sector | Health | Technology |
52-Week High | $277.18 | $301.71 |
52-Week Low | $163.32 | $84.39 |
Enterprise Value | $18.11B | $303.62B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
KLA Corporation (KLAC) trades at $231.52, up 0.88% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.94 exceeding the $0.917 estimate. Revenue grew to $12.16 billion in 2025, driving a net income margin of 35.66%. A 1:10 stock split is scheduled for June 12, 2026, and a $2.30 dividend was paid in June 2026.
KLAC's outlook is supported by AI-driven semiconductor equipment demand and consistent earnings outperformance, but high valuation ratios (P/E 65.57, P/S 23.38) pose risks if growth slows. Analysts maintain a buy consensus with a $239.86 price target, though competitive pressures and market volatility remain concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
